![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
1. (s)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide
2. Darifenacin
3. Darifenacin Hydrochloride
4. Darifenacine
5. Darifenicin
6. Emselex
7. Enablex
8. Uk-88525
1. Darifenacin Hbr
2. 133099-07-7
3. Emselex
4. Darifenacin (hydrobromide)
5. Darifenacin Hydrobromide [usan]
6. Cr02eyq8gv
7. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide Hydrobromide
8. Uk-88525-04 (hydrobromide)
9. Chebi:31455
10. Uk-88525-04 (hbr)
11. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide Hydrobromide
12. 133099-07-7 (hbr)
13. Dsstox_cid_26780
14. Dsstox_rid_81899
15. Dsstox_gsid_46780
16. (s)-2-{1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl}-2,2-diphenylacetamide Hydrobromide
17. Uk-88525
18. Darilong
19. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
20. Uk 88525-04 Hydrobromide
21. Cas-133099-07-7
22. Ncgc00168775-01
23. Unii-cr02eyq8gv
24. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hydrobromide
25. 2-{(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide Hydrobromide
26. Enablex (tn)
27. Darifenacinhydrobromide
28. Diphenyl-acetamide Hydrobromide
29. Darifenacin Hydrobromide- Bio-x
30. Chembl1200935
31. Dtxsid9046780
32. Hy-a0012
33. Tox21_112636
34. Darifenacin Hydrobromide (jan/usan)
35. Darifenacin Hydrobromide [mi]
36. Mfcd08141803
37. S3144
38. Darifenacin Hydrobromide [jan]
39. Akos015969311
40. Tox21_112636_1
41. Ac-1894
42. Ccg-220969
43. Cs-0380
44. Darifenacin Hydrobromide [mart.]
45. Darifenacin Hydrobromide [usp-rs]
46. Darifenacin Hydrobromide [who-dd]
47. Ncgc00263922-02
48. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (3s)-
49. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (s)-
50. 3-pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-alpha,alpha-diphenyl-, Hydrobromide (1:1), (3s)-
51. As-35087
52. Bd164350
53. Darifenacin Hydrobromide [ema Epar]
54. Darifenacin Hydrobromide, >=98% (hplc)
55. Sw219426-1
56. Darifenacin Hydrobromide [orange Book]
57. Uk-88525-04
58. D01699
59. Q-101006
60. Q27114313
61. Z1691545283
62. Darifenacin Hydrobromide, United States Pharmacopeia (usp) Reference Standard
63. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hbr
64. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohbr, (3s)-
65. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohydrobromide, (3s)-
Molecular Weight | 507.5 g/mol |
---|---|
Molecular Formula | C28H31BrN2O2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 7 |
Exact Mass | 506.15689 g/mol |
Monoisotopic Mass | 506.15689 g/mol |
Topological Polar Surface Area | 55.6 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 607 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Darifenacin hydrobromide |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | oral |
Strength | 7.5mg; 15mg |
Market Status | Tentative Approval |
Company | Anchen Pharms |
2 of 4 | |
---|---|
Drug Name | Enablex |
PubMed Health | Darifenacin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | ENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[... |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 15mg base; eq 7.5mg base |
Market Status | Prescription |
Company | Warner Chilcott |
3 of 4 | |
---|---|
Drug Name | Darifenacin hydrobromide |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | oral |
Strength | 7.5mg; 15mg |
Market Status | Tentative Approval |
Company | Anchen Pharms |
4 of 4 | |
---|---|
Drug Name | Enablex |
PubMed Health | Darifenacin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | ENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[... |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 15mg base; eq 7.5mg base |
Market Status | Prescription |
Company | Warner Chilcott |
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
G04BD10